Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Toripalimab and Gemcitabine in Cisplatin-Ineligible Bladder Cancer
NCT04553939Phase 2Completed
- Sponsor
- Henan Cancer Hospital
- Start
- Jan 2021
- Primary completion
- Apr 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of toripalimab in bladder cancer, sponsored by Henan Cancer Hospital. Primary endpoint: Objective Response Rate at 3 years. Started Jan 2021; status: completed.
02
Drugs
toripalimab
03
Conditions
bladder cancer
Beyond the preview
Go deeper on NCT04553939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04553939.